

16 September 2010 EMA/HMPC/131901/2009 Committee on Herbal Medicinal Products (HMPC)

Community herbal monograph on *Thymus vulgaris* L. *Thymus zygis* Loefl. ex L., aetheroleum

This document was valid from 16 September 2010 until July 2020. It is now superseded by a <u>new version</u> adopted by the HMPC on 8 July 2020 and published on the EMA website.

list (MLWP)	May 2009
Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation	14 May 2009
End of consultation (deadline for comments). Comments should be provided using this template to hmpc.secretariat@ema.europa.eu	15 September 2009
Rediscussion in Working Party on Community monographs and	November 2009
Community list (MLWP)	January 2010
Adoption by Committee on Herbal Medicinal Products (HMPC)	16 September 2010

Keywords Herbal medicinal products; HMPC; Community herbal monographs; traditional use; *Thymus vulgaris* L., *Thymus zygis* Loefl. ex L.; Thymi aetheroleum; thyme essential oil, thyme oil

BG (bălgarski): Неприложимо.	LT (lietuvių kalba): Duomenys nebūtini.
CS (čeština): Neuplatňuje se.	LV (latviešu valoda): Nav piemērojams.
DA (dansk): Ikke relevant.	MT (malti): Ma jgħoddx.
DE (Deutsch): Nicht zutreffend.	NL (nederlands): Niet van toepassing.
EL (elliniká): Άνευ αντικειμένου.	PL (polski): Nie dotyczy.
EN (English): Not applicable.	PT (português): Não aplicável.
ES (espanol): No procede.	RO (română): Nu este cazul.
ET (eesti keel): Ei ole asjakohane.	SK (slovenčina): Neuplatňuje sa.
FI (suomi): Ei sovelleta.	SL (slovenščina): Navedba smiselno ni potrebna.
FR (français): Sans objet.	SV (svenska): Erfodras ej.
HU (magyar): Nem értelmezhető.	IS (íslenska): A ekki vid.
IT (italiano): Non applicabile.	NO (norsk): Ikke relevant.

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom **Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7051 **E-mail** info@ema.europa.eu **Website** www.ema.europa.eu



An agency of the European Union

 \odot European Medicines Agency, 2010. Reproduction is authorised provided the source is acknowledged.

Community herbal monograph on *Thymus vulgaris* L., *Thymus zygis* Loefl. ex L., aetheroleum

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition $1,^2$

Well-established use	Traditional use
	With regard to the registration application of
	Article 16d(1) of Directive 2001/83/EC as
	amended
	Thymus vulgaris L. or Thymus zygis Loefl. ex L. or
	a mixture of both species, aetheroleum (thyme
	oil)
	i) Herbal substance
	Not applicable.
	ii) Herbal preparations
	Essential oil.

3. Pharmaceutical form

In liquid dosage forms for oral use (indication 1)
and in liquid or semi-solid dosage forms for cutaneous use and use as a bath additive (indication 2). The pharmaceutical form should be described by
the European Pharmacopoeia full standard term.

¹ The material complies with the Ph. Eur. monograph (ref.: 01/2008:1374).

² The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

Community herbal monograph on Thymus vulgaris L., Thymus zygis Loefl. ex L., aetheroleum EMA/HMPC/131901/2009

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	Indication 1)
	Traditional herbal medicinal product used as an expectorant in cough associated with cold.
	Indication 2)
	Traditional herbal medicinal product for the relief of symptoms in coughs and colds.
	The product is a traditional herbal medicinal
	product for use in specified indications exclusively based upon long-standing use.
4.2. Posology and method of adminis	tration

4.2. Posology and method of administration

Well-established use	Traditional use
	Posology
	Indication 1)
	Adults and elderly
	Oral use: 4-5 drops (single dose), 3-5 times daily.
	The oral use in children and adolescents under 18 years of age is not recommended (see 4.4 Special warnings and precaution for use). Indication 2)
	Adults and elderly
	Cutaneous use: in liquid and semi-solid dosage forms in concentrations up to 10%; apply up to 3 times daily. Use as bath additive: 0.007 – 0.025 g per litre.
	Adolescents
	Use as bath additive: 0.007 – 0.025 g per litre.
	Children 6-12 years
	Use as bath additive: 0.0035 – 0.017 g per litre.
	Children 3-6 years
	Use as bath additive: 0.0017 – 0.0082 g per litre.
	One bath every day or every second day.
	The cutaneous use in children and adolescents

	under 18 years of age is not recommended (see 4.4 Special warnings and precaution for use).
	The use as bath additive in children under 3 years of age is not recommended (see 4.4 Special warnings and precaution for use).
	Duration of use
	Indication 2)
	Duration of a bath: 10-20 minutes.
	Indications 1) and 2)
	If the symptoms persist longer than 1 week, a
	doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Indication 1)
	Oral use.
	Indication 2)
	Cutaneous use: apply on the chest and the back.
	Use as bath additive: recommended temperature
	of bath: 35 – 38 °C.
4.3. Contraindications	

4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance.
	Use as bath additive:
	Full baths are contraindicated in cases of open
	wounds, large skin injuries, acute skin diseases,
	high fever, severe infections, severe circulatory
	disturbances and cardiac insufficiency.

4.4. Special warnings and precautions for use

Well-established use	Traditional use
	Indication 1)
	Like other essential oils Thyme oil should not be
	applied to the face particularly in the nasal area of
	babies and infants under the age of two years
	because of the risk of a laryngospasm.
	When dyspnoea, fever or purulent sputum occurs,
	a doctor or a qualified health care practitioner

should be consulted.
should be consulted.
The use in children and adolescents under 18
years of age is not recommended due to lack of
adequate data.
Indication 2)
Use as bath additive:
When dyspnoea, fever or purulent sputum occurs,
a doctor or a qualified health care practitioner should be consulted.
The use in children under 3 years of age is not recommended because medical advice should be
sought and due to lack of adequate data.
In cases of hypertension, a full bath should be used with caution.
Cutaneous use:
Like other essential oils Thyme oil should not be applied to the face particularly in the nasal area of
babies and infants under the age of two years
because of the risk of a laryngospasm.
When dyspnoea, fever or purulent sputum occurs,
a doctor or a qualified health care practitioner
should be consulted.
The use in children and adolescents under 18
years of age is not recommended due to lack of
adequate data.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported.

4.6. Pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established.
	In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use	
	No studies on the effect on the ability to drive and use machines have been performed.	

4.8. Undesirable effects

Well-established use	Traditional use
	Indication 1)
	Hypersensitivity reactions have been observed.
	The frequency is not known.
	Indication 2)
	Hypersensitivity reactions and skin irritation have
	been observed. The frequency is not known.
	If other adverse reactions not mentioned above
	occur, a doctor or a qualified health care
	practitioner should be consulted.
4.9. Overdose	

4.9. Overdose

Well-established use	Traditional use	
	No case of overdose has been reported.	

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use	
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.	

5.2. Pharmacokinetic properties

Well-established use	Traditional use	
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.	

5.3. Preclinical safety data

Well-established use	Traditional use	
	Not required as per Article 16c(1)(a)(iii) of	
	Directive 2001/83/EC as amended, unless	

necessary for the safe use of the product.
Thyme essential oil had no mutagenic or DNA- damaging activity in either the Ames test (strains TA1535, TA1537, TA98, TA100, with and without metabolic activation) or Bacillus subtilis rec-Assay.
Adequate tests on reproductive toxicity and carcinogenicity have not been performed.

6. Pharmaceutical particulars

Well-established use	Traditional use	$\overline{\mathbf{O}}$
	Not applicable.	

7. Date of compilation/last revision

16 September 2010